Browsing Tag

PC14586

PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in…

Jason Junior Jul 19, 2022

CRANBURY, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53,…

Health

PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of…

Jason Junior Apr 27, 2022

Oral presentation at ASCO to highlight initial data from ongoing Phase 1 study of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a p53 Y220C mutation CRANBURY, N.J.,…